Alnylam’s RNA Interference Approach Wins FDA Approval for ATTR-CM Treatment
Alnylam Pharmaceuticals has secured FDA approval for its RNA interference treatment, Amvutra (vutrisiran), as a new therapy for transthyretin amyloid cardiomyopathy (ATTR-CM). This marks a significant milestone for the Massachusetts-based biotech firm, which aims to differentiate its approach from existing treatments. The FDA has granted Amvutra approval for treating ATTR-CM in adults, with the goal … Read more